M. Nowak - Res & Early Dev, Bristol Myers Squibb

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 34 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Improvements in Patient-Reported Outcomes after Treatment with Deucravacitinib in Patients with Psoriatic Arthritis: Results from a Randomized Phase 2 Trial

Vibeke Strand,Laure Gossec,Laura C. Coates,Alexis Ogdie,Jiyoon Choi,Brandon Becker,Joe Zhuo,Thomas Lehman,Miroslawa Nowak,Ayanbola Elegbe,Philip J. Mease,Atul Deodhar

ARTHRITIS CARE & RESEARCHno. 8 (2024): 1139-1148

引用0浏览0WOS引用

EFFICACY OF THE ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA)

Alice B. Gottlieb,April W. Armstrong,Joseph F. Merola,Andrew Napoli,Miroslawa Nowak,Subhashis Banerjee, Thomas Lehman,Philip J. Mease

ACTA DERMATO-VENEREOLOGICA (2024)

引用0浏览0引用

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated with Disease Activity, Pharmacodynamics, and Clinical Responses

Oliver Fitzgerald,Dafna D. Gladman,Philip J. Mease,Christopher Ritchlin,Josef S. Smolen,Lu Gao,Yanhua Hu,Miroslawa Nowak,Subhashis Banerjee,Ian Catlett

ARTHRITIS & RHEUMATOLOGYno. 9 (2024): 1397-1407

引用0浏览0WOS引用

DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS

A. Kavanaugh,L. Coates,J. F. Merola,P. J. Mease,M. Nowak,S. Banerjee,L. Hippeli,T. Lehman

Rheumatology (Oxford, England)（2024）

引用0浏览0WOS引用

POS1550 IMPACT OF ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 TRIAL

A. B. Gottlieb,A. Armstrong,J. F. Merola,A. Napoli,M. Nowak, S. Banerjee,T. Lehman, P. J. Mease

Scientific Abstracts (2023)

引用0浏览0引用

Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial

Lihi Eder,Alexis R. Ogdie,Subhashis Banerjee,Miroslawa Nowak,Thomas Lehman,Philip J. Mease

ARTHRITIS & RHEUMATOLOGY (2023): 945-947

引用0浏览0引用

Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA

Philip J. Mease,Lihi Eder, Alexis R. Ogdie,Atul Deodhar,Subhashis Banerjee,Miroslawa Nowak, Jiyoon Choi, Thomas Lehman,Vibeke Strand

ARTHRITIS & RHEUMATOLOGY (2023): 992-994

引用0浏览0引用

Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes in a Phase 2 Clinical Trial of Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Active PsA: A Mediation Analysis

Philip J. Mease,Lihi Eder, Alexis R. Ogdie,Atul Deodhar,Subhashis Banerjee, Ying-Ming Jou,Miroslawa Nowak, Thomas Lehman,Vibeke Strand

ARTHRITIS & RHEUMATOLOGY (2023): 994-996

引用0浏览0引用

Evaluation of BMS-986142, a Reversible Bruton's Tyrosine Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: a Phase 2, Randomised, Double-Blind, Dose-Ranging, Placebo- Controlled, Adaptive Design Study

Philip G. Conaghan,Miroslawa Nowak,Shuyan Du,Yi Luo,Jessica Landis,Chahin Pachai,Aberra Fura,Ian M. Catlett,Dennis M. Grasela,Mikkel Ostergaard

The Lancet Rheumatologyno. 5 (2023): e263-e273

引用0浏览0WOS引用

Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial

Alice B. Gottlieb,April W. Armstrong,Joseph Merola,Andrew Napoli,Miroslawa Nowak,Subhashis Banerjee,Thomas Lehman,Philip J. Mease

ARTHRITIS & RHEUMATOLOGY (2023): 2782-2785

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn